Skip to main content

Table 1 Clinical, methylation and CGH data for prostate cancer tissues

From: Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer

Tumor No.

Stage

Gleason Score

Molecular Group

LINE-1 %hypo

No. hypem. genes

Chromosomal losses

Chromosomal gains

36

pT3bN0

7

 

1

4

-

3q21q26.2

38

pT2N0

7

 

4

4

-

-

50

pT3bN0

7

hypo

10

4

1q31

6p,7p,16p,17p, 18p,19, 20q13,21,22,Y

65

pT3bN0

7

both

9

4

Y

1p33p34.3, 2p21p23, 2q14.1q14.3, 2q33q36, 3p14.1p21.3, 3q25.1q26.3, 4q13.3q28, 5q22, 5q31.2q32, 6q16.1q22.1, 8q22.1q23, 10p11.2p13, 10q11.2q22.3, 12q13.2q24.31, 13q21.1q31, 14q21q32.2, 18q11.2q22, Xp21.3q27

83

pT3bN0

7

hypo

6

4

1q31, 2q33q37, 4q31, 13q21q31, 15q24,

4q12, 5q13, 17p, 18p, 19, Y

89

pT2bN0

3

hypo

5

2

9q33q34, X

2q11q24, 4q12q22, 6q22, 12p,18p, Y

93

pT3bN0

7

 

4

4

-

Yq

95

pT3bN1

10

hypo

7

4

Xq

18p, Y

99

pT2bN0

5

 

0

1

-

2q14q24,10q11q21

101

pT3aN0

8

none

0

3

1p36, 14q31q32, 17p, 22

-

105

pT3aN0

5

 

1

1

1p36,2,3,4

-

107

pT3aN0

7

none

3

4

18p, Y

4q24, 6q22, Xp11.2p11.4

117

pT3bN0

5

 

3

4

-

1q21q25,2q11q14,19q13

119

pT3bN1

9

none

1

3

7p15pter, 15q23qter, Y

10q21q22

121

pT2bN0

6

chrom8

1

4

1q32q41, 3p21, 4p15p16, 8p22p23, 9p23p24,10q25q26, 11q23q25, 12q24, 13q32q34, 14q24q32, 15q24q26, 17q24q25, Xp21p22

Yq

123

pT2aN0

5

 

1

1

9q21.2q21.3, 10q26, 16p, Y

2p14p16, 2q24.3q32.1, 6q14q16.1

125

pT2bN0

6

 

1

0

14q31

-

127

pT2bN0

7

none

2

2

7q36, Yq

2q22q32.3, 4q11q31.3, 13q14.1q21.1, 14q21q23, 15q21.1q23

133

pT2bN1

7

chrom8

0

4

22, Y

1q, 2q22q34, 3q11.1q26.1, 4q22q27, 5q21q31, 6q21q24, 8q11q23, 10q11q21.3, 12q21q22, 14q12q22, X

137

pT2bN0

8

chrom8

1

1

16, 17, 18p, 18q11.1q21.1, 19, 21q22, Y

3q23q26.3, 4q13.2q21.3, 5q, 7q13q31, 8p21pter, 8q24, 9p, 14q13qter

139

pT3bN1

9

chrom8

1

4

19q, Y

1q25q31, 2q11q33, 3, 4q, 5q13q23, 6q14q25, 7q21qter, 8q13q23, 11q14qter, 13q21q32, 14q11.1q21, 18q12, Xq21.3qter

141

pT2bN0

4

chrom8

0

2

16, 17, 18p, 19, 20, 22, Y

1q31q32.1, 2, 3q13.3qter, 4q11q31.1, 5q14qter, 6q, 7p12pter, 7q22q31.2, 8q12q21.2, 10q21.1q23.1, 11q14.3qter, 12q14qter, 13q14.1qter

145

pT4N1

7

hypo

11

3

Y

3q25q27,4q24q26,7q11q22,13q31q34,17p,18p

149

pT2bN0

6

 

2

2

Y

2p, 4p12, 4q24q26, 5q11q13, 7p12, 8q23q24, 9,11q22, 12q12q15, 14q24, 17, 19, 20q13,

151

pT3aN0

7

 

0

1

3p13p14

6p14, Xp21

153

pT3aN0

5

 

2

1

 

Xq11.2q13

155

pT3aN0

5

 

5

4

19p

3p25p26, Y

157

pT2aN0

8

 

2

0

-

1q21q31, 2q12q24, 3q, 4q12q21, 5q13q14, 6q14q16, 7q11, 8q12q22, 12q12q13, 18p, Y

161

pT2bN0

5

 

3

4

15q22q24, Xq22q25

-

163

pT3bN1

5

chrom8

2

2

16, 17p, 18p, 20, Y

1q25qter, 2p11p16, 2q32q34, 3q12, 3q21q27, 4q, 6q15q24, 8q12q21, 8q23q24, 12q13q21, 13q14q32, 14q12q21, 18q, Xq11.1q26

169

pT3aN0

7

chrom8

3

2

16, 17p, 18p, 19, Y

2, 3, 4q, 5q, 7p15pter, 8q22q24, 13q31qter, 14q24qter, 17q23, 18q21qter, Xq21.3q26

171

pT2bN0

5

hypo

8

4

10q26, 18p. -19, 22, Y

1p31, 2p12p13, 2q11q34, 4q22q26, 5q22, 6q11q23, 14q22q24, X

175

pT2bN0

8

 

11

4

13q14

-

183

pT3aN0

6

 

19

4

1p36,9q34

-

187

pT2bN0

8

chrom8

1

3

16, 17p, 18p, 19, 21, 22, Y

1, 2, 3q13qter, 4q, 5q14q33.1, 6q16q23, 7p, 7q22q33, 8q, 11q14.3qter, 12q14qter, 13q21qter, 14q24q31, 15q, Xq22qter

189

pT2bN0

7

none

0

4

3p25p26, 10q26, Xq22qter, Yq

-

191

pT2bN0

7

 

0

3

4q31, 5q31q35, 9q33, 12p12

-

205

pT3aN0

7

 

5

1

18p, 19, 22, Y

2q31q33, 6q22.3q23, 10q21q22, Xp11.1p11.4, Xq

209

pT3aN0

7

both

8

4

1p36, 8p, 16, 17, 18p, 19, 20, 22, Y

1q31q32.1, 2q11.1q34, 3, 4q21.1qter, 5q14q31, 6q11q23, 7q21q34, 8q, 9, 11q14q22, 12q15q24, 13q14qter, 18q

213

pT2aN0

7

 

8

4

8q24.2qter, 14q32, 16, 17, 18p, 22, Y

-

215

pT3aN0

7

 

9

4

19q13, 22q13,Y

3q24q26, 5q12, 8p12, 17, 18, Xp11p21, X21q24

217

pT2bN0

8

 

5

4

18p13, Y

2q33q35, 4q13q28,5q21q31,8q21,8q24,12q13, 12q21q23, Xq13q25

219

pT4N1

7

both

21

4

5q34qter, 8p22pter, 19, Yq

1p22p31.3, 4q21q22, 4q31.1, 5q13, 6q24q26, 7q, 8q21q24, 10q21, 11q14q22, 20q13, Xq13q22

225

pT3bN0

6

 

4

4

4q28, 8q24qter, Yq

-

227

pT2aN1

7

 

3

4

22q13

3q11q21

232

pT2bN1

7

both

13

4

8p22pter

-

245

pT3aN0

7

 

4

3

17p13, 18p

1p31

247

pT3bN1

7

chrom8

3

3

8p21pter, 9q21, 22, Y

Xq12

253

pT3aN1

7

 

1

4

1p36, 2q33q37, 6p21.3p25, 8p21, 14q31q32, Y

-

256

pT3bN0

7

 

1

4

2p2p21, 6q, 15q26,16p, 18,X

-

  1. The numbers of the tumors used in the microarray analysis are in bold type, as are hypomethylation values considered significantly elevated (< 4%) and typical chromosome 8 aberrations. All cancers were M0 at the time of prostatectomy. No. hypermethylated genes indicates hypermethylation of APC, GSTP1, RARB2, and RASSF1A. LINE-1 hypomethylation was determined by Southern blot analysis. Chromosomal dosage changes were determined by comparative genomic hybridization.